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ABSTRACT  
The endothelin axis, and in particular the two endothelin receptors, ETA and ETB, are targets 
for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical 
use to treat pulmonary arterial hypertension and have been under clinical investigation for the 
treatment of several other diseases, such as systemic hypertension, cancer, vasospasm and 
fibrogenic diseases. In this Perspective, we review the molecules that have been evaluated in 
human clinical trials for the treatment of pulmonary arterial hypertension, as well as other 
cardiovascular diseases, cancer and fibrosis. We will also discuss the therapeutic 
consequences of receptor selectivity with regard to ETA-selective, ETB-selective or dual 
ETA/ETB antagonists. We will also consider which chemical characteristics are relevant to 
clinical use and the properties of molecules necessary for efficacy in treating diseases against 
which known molecules displayed suboptimal efficacy.  
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INTRODUCTION 
The endothelin axis 
The endothelin (ET) axis is mainly recognized for its action as a potent vasoconstrictor 
system involved in the regulation of vascular tone, but it has pleiotropic other functions able 
to mediate fundamental cellular processes such as cell proliferation and apoptosis. Thus, 
beside its normal functions the endothelin axis has also been involved in human hypertensive 
and cardiovascular pathologies and in fibrogenic, inflammatory and oncologic diseases, and 
has putative roles in other pathologies including septic shock, atherosclerosis, heart failure, 
renal insufficiency and cerebrovascular conditions associated with subarachnoid hemorrhage.  
The endothelins (ET-1, ET-2 and ET-3) constitute a family of 21 amino-acid (aa) peptides 
synthesized as longer precursor polypeptides of 212 aa (ppETs). These peptides are further 
proteolytically cleaved by a signal peptidase to produce pro-ET-1, and further activated by a 
subtilisin-like convertase/furin-like protease that release the 38 aa-long pro-ETs (big ETs). 
Big ETs are then subsequently cleaved by the more specific membrane-bound endothelin 
converting enzyme-1 (ECE-1)1 to yield the 21-aa active ET peptides. Following their 
proteolytic processing, the ET peptides can be either constitutively secreted or can be stored 
in intracellular granules, then secreted according to a regulated pathway in response to a 
stimulus.2 Following activation and secretion, ET peptides act on two distinct high-affinity 
receptor subtypes, ETA and ETB, which are located on target cell membranes.3  
The cell and tissue expression of the components of the endothelin axis are numerous. The 
vascular endothelium is an abundant source of the components of the endothelin axis; 
however, they may also be expressed by leukocytes, smooth muscle cells, mesangial cells, 
cardiac myocytes, or astrocytes. The most representative peptide of the axis, endothelin (ET)-
1, can be induced in endothelial cells by many factors including mechanical stimulation, 
various hormones and pro-inflammatory cytokines. Its production is inhibited by nitric oxide 
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(NO), cyclic nucleotides, prostacyclin and atrial natriuretic peptide (ANP). ET-1 also 
stimulates cardiac contraction and the growth of cardiac myocytes, regulates the release of 
vasoactive substances, and stimulates smooth muscle cell mitogenesis. ET-1 may control 
inflammatory responses by promoting the adhesion and migration of neutrophils and by 
stimulating the production of pro-inflammatory cytokines. It has also been implicated in 
cancer progression, regulating the proliferation and migration of tumor cells and acting as a 
pro-angiogenic factor and an inducer of stromal reaction.  
In this Perspective, we will first describe the components of the endothelin axis, then, we 
will discuss attempts made to therapeutically control the functions of the endothelin axis in 
diseases. We will also discuss and evaluate in more detail the therapeutic interest of 
endothelin-receptor antagonists in three pathological conditions of proliferative fibrogenic 
disorders: 1) pulmonary arterial hypertension (PAH), for which endothelin-receptor 
antagonists are in clinical use; 2) cancer, for which clinical trials have been launched but for 
which no antagonist has yet reached clinical use; and finally 3) fibrogenic diseases of the 
kidney, for which such antagonists are being considered for therapy. Fibrogenic disorders 
involve the recruitment of inflammatory/immune cells, which ultimately drive the activation 
and proliferation of fibroblasts and the replacement of tissue cells by these activated 
(myo)fibroblasts. These three conditions imply an enhanced proliferative component 
involving different but complementary cells. Not surprisingly, as ET-1 and its associated 
components, are cell-proliferation, anti-apoptotic, pro-survival and contractile factors, they 
have been evaluated as therapeutic targets for these potential therapeutic possibilities. Only 
drugs able to inhibit the binding of ETs to their cognate ETA and/or ETB receptors, the 
“sentan” family of endothelin-receptor antagonists, have reached clinical evaluation and use 
and will be described in detail in this Perspective.  
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   The components of the endothelin axis  
The endothelin peptides: ET-1, ET-2 and ET-3 
The most-studied peptide from the ET family, endothelin-1 (ET-1), was discovered in 19884 
as a potent and long-lasting vasoconstrictor peptide, much more potent than angiotensin II. 
The 21-aa active ET peptides are characterized by a single alpha helix, two essential disulfide 
bridges, Cys3-Cys11 and Cys1-Cys15, and six conserved amino acid residues at the C-
terminus. ET-1 has been the most studied peptide of the family; however, the other peptides 
of the endothelin family, ET-2 and ET-3 may also be of therapeutic interest.5 A role for ET-2 
is emerging in ovarian development, the cardiovascular system, immunology and cancer. In 
human, ET-2 differs from ET-1 by only two amino acids and has the same affinity as ET-1 for 
ETA and ETB receptors, unlike ET-3. Until recently, it was assumed that ET-2 mimics the 
functions of ET-1; however, recent evidence has pointed to a specific ET-2 pathway as a key 
regulator of ovarian contractile physiology, with roles as well in heart failure, immunology 
and cancer. ET-3 differs from ET-1 by six amino acids and has differential affinities for ETA 
and ETB, being highly selective for ETB. ET-3 is the main ET peptide in the central nervous 
system. In cancer, ET-2 and ET-3 may counteract the functions of ET-1, but are also 
frequently silenced. In human, the genes encoding for ET-1, ET-2 and ET-3 are located on 
chromosomes 6, 1 and 20, respectively. Epigenetic inactivation by hypermethylation of ET-2 
and ET-3 promoters in colon cancer was postulated to favor ET-1-mediated tumor 
progression., suggesting that ET-2 and ET-3 are natural antagonists of ET-1 and that re-
expression of ET-2 and ET-3 may be a complementary approach to receptor antagonists.6 The 
activation of ET precursors by ECEs and chymase may also allow the selective activation of 
one of the pathways.   
   The endothelin activating enzymes: furins and endothelin-converting enzymes 
Furins are a family of intracellular serine proteases belonging to the subtilisin-like 
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proprotein convertase family. The members of this family process latent precursor proteins at 
paired basic amino-acid sequences (Arg/Lys-Arg) into their biologically active products. 
These endoproteases can cleave many precursor proteins, including ppETs, and are involved 
in several human disorders.7 Furins are mainly located within the Golgi/trans-Golgi secretory 
pathway. The catalytic mechanism in enzymes of the serine protease family involves a 
catalytic triad consisting of three essential amino acids: one histidine, one serine and one 
aspartic acid. In the enzymatic mechanism, covalent intermediates are generated. Inhibitors of 
furins, which include α1-antitrypsin, polyarginine compounds, decanoyl-Arg-Val-Lys-Arg-
chloromethylketone, as well as a few synthetic molecules, are under consideration as 
therapeutic agents.8 However, to the best of our knowledge, no therapeutic attempts have been 
made to control the endothelin axis with furin inhibitors. 
   Two metalloprotease endothelin-converting enzymes (ECEs) have been described.1,9-12 
ECE-1 (EC 3.4.24.71) hydrolyzes the Trp11-Val12 bond of human bigET-1 at neutral pH and 
is expressed as four isoforms, ECE-1a-d, from one gene through the use of different promoters. 
ECE-2 is active at acidic pH, but as little information exists concerning its physiological 
importance in human diseases, it will not be discussed in this Perspective. The effect of 
inhibition of ECE-1 has been evaluated only in animal models of cardiovascular disorders and 
in vitro in cancer13 and will not be reviewed in detail here because no human trials for 
therapeutic purposes have been published with these inhibitors.14 However, some 
observations may be of interest. Depending on the particular ECE-1 isoform or on external 
factors, ECE-1 may be secreted or expressed at the cell surface (ECE-1a and ECE-1c) and thus 
may be directly accessible to inhibitors. Alternatively, ECE-1 may remain intracellular (ECE-
1b and ECE-1d), thus necessitating that inhibitors traverse the cell membrane. NEP 
24.11/neprilysin may also activate and degrade big-ET-1, but with a much lower efficiency 
than ECE-1.15 Some information also suggests that mast-cell-derived chymase cleaves the 
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Tyr31-Gly32 bond of big-ET-1 to yield ET-1 (1-31). This peptide is further processed into the 
active ET- (1-21) by either ECE-1, the main activator of big-ET-1, or NEP24.11, as both 
thiorphan (a selective NEP 24.11 inhibitor) and phosphoramidon (a dual ECE-1/NEP24.11 
inhibitor) abolish ET-1 (1-31) processing.16 The enzymes of this latter pathway and their 
inhibitors have not been evaluated in much detail for therapeutic purposes, and this alternate 
pathway will not be discussed further here. However, while pure ECE-1 inhibitors have not 
been tested in the clinic, dual ECE-1/ACE inhibitors have been evaluated in clinical trials.17,18  
The endothelin receptors: ETA and ETB 
ET receptors belong to the family of seven transmembrane G-protein-coupled receptors 
(GPCR). Heterotrimeric guanine nucleotide-binding G proteins, composed of α-, β-, and γ-
subunits on the inner membrane surface of the cells, are key determinants of many signaling 
processes, including cell proliferation, apoptosis, survival, contraction, migration and/or 
differentiation. GPCR ligands interact with many downstream effectors, including adenyl 
cyclases, phosphodiesterases, phospholipases, tyrosine kinases and ion channels. The duration 
of the signal is modulated by the activity of the multiple GPCR-mediated signaling pathways, 
leading to diverse biological responses.19,20 At physiological concentrations, ET-1 and ET-2, 
but not ET-3, bind to ETA receptors with comparable affinity (KD ET-1 = ET-2 ~ 20-60 pM, 
ET-3 ~ 6500 pM), whereas all three ET ligands bind ETB receptors with similar affinity (KD 
ET-1 = ET-2 = ET-3 ~ 15 pM). In humans, ETA is located in the vasculature and is mostly 
expressed by cells of the vascular smooth muscle lineage. In these cells, binding of ET-1 to 
ETA mainly induces vasoconstriction and cell proliferation. ETB in the vasculature is mostly 
expressed by endothelial cells. In these cells, binding of ETs to ETB induces vasodilatation, 
bronchoconstriction and cell proliferation. In the endothelium, ET-1 is mainly released 
abluminally, rather than into the blood stream, suggesting autocrine/paracrine-localized tissue 
functions rather than endocrine functions; however, other cell types have been shown to 
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express and respond to the components of the endothelin axis. For example, mutations in ETB 
in the colon is associated with Hirschprung disease and selective expression of both receptors 
is seen in cancer cells and cancer-associated stromal cells (see below). In human, the genes 
encoding for ETA and ETB are located on chromosomes 4 and 13, respectively.  
Both ETA and ETB receptors share common signal-transduction pathways through 
phosphatidylinositol hydrolysis and an increase in cytosolic calcium. The two receptors can 
also signal through different G proteins and stimulate a variety of other effector systems such 
as phospholipases D and A2, PKC or the protein tyrosine kinase-MAP-kinase/ERK 
pathways.21,22 The transactivation of the EGF receptor by ET-1 has also been reported.10 In 
addition to its potent vasoconstrictor activity, ET-1 is an autocrine/paracrine (co-)mitogen in 
many cell types, involving several intracellular signaling pathways. Antagonists to endothelin 
receptors have been developed for the treatment of several cardiovascular diseases23-27 and 
have reached clinical use in the case of pulmonary hypertension.28 Unexpectedly, they have 
also shown promising effects in the context of cancer, with the potential to control tumor 
growth and potentiate apoptosis, as well as in fibrotic processes in kidney disorders.  
Variants of both endothelin receptors have been described,29-38 and mutagenesis and 
chimeric receptor studies have indicated that splice variants of the endothelin receptors may 
undergo conformational changes. It can be speculated that these changes may allow either the 
binding of ligands other than the ETs or the binding of cellular proteins able to modify the 
biological functions of the receptors, resulting in either increased or decreased binding 
affinities for receptor agonists and antagonists and changes in signaling pathways. Several 
studies have shown that the loss of ETB receptor functions plays an important role in ET-
induced proliferation and cell death, as well as the activation of intracellular signal 
transduction pathways that regulate ET production. These effects of ETB receptor functions 
may be important in tumor development, both in cancer cells and cancer-associated stromal 
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cells. We have searched for ETB variants in human glioblastoma (GBM) cells (Y Berger and 
L Juillerat-Jeanneret, unpublished data) and in human melanoma cells.39 Our results suggested 
cell-selective effects and possibly methylation of the ETB promoter. Methylation of the 
EDNRB gene was also observed by others in cancer but was not predictive of survival.40 
However, a quantitative analysis comparing promoter methylation of the EDNRB gene in 
paired human normal and gastric tumors found a correlation between higher methylation rates 
and the aggressiveness and progression of the cancer.41  
   The therapeutic control of the endothelin axis in human diseases 
The endothelin axis has been widely implicated in the pathophysiology of various human 
diseases. As ET-1 is a very potent vasoconstrictor peptide, the first therapeutic attempts aimed 
at treating hypertensive disorders, then it was realized that the components of this axis may 
also be valuable therapeutic targets in cancer, inflammation, fibrosis and metabolic diseases. 
For therapeutic purposes, the endothelin axis may be blocked using chemical tools, either at 
the level of bigET activation (using inhibitors of ECE-1) or by using antagonists to the ETA 
and/or ETB endothelin receptors (Figure 1). In many academic and industrial groups, 
programs were initiated for the design, preparation and evaluation of molecules aimed at 
controlling the functions of the endothelin axis, the bioprocessing of ET-1 by its activating 
enzymes and its binding to its cognate receptors, ETA and/or ETB. These two strategies have 
been evaluated in animal experimental models of human diseases; however, only receptor 
antagonists have reached clinical trials and clinical use.  
 
 10 
 
Figure 1. The metabolic processing of the components of the endothelin axis and the potential 
sites of control of the functions of the endothelin axis (insert, 1 to 7). ET: endothelin; ECE: 
endothelin converting enzyme-1. Many different types of cells can secrete the ET peptides 
and express the ET receptors. Following ET gene activation, a precursor polypeptide is 
sequentially hydrolyzed by a signal peptidase, a furin-like convertase, then the ECE-1, either 
by intracellular ECE isoforms or at the cell surface by cell-membrane inserted ECE, to yield 
the 21-aa active ET. ET can be either constitutively secreted or can be secreted according to a 
regulated pathway in response to a stimulus. Then, ET acts on two distinct receptors ETA and 
ETB, to induce intracellular signaling. In this drawing, a paracrine effect of ET is shown, 
however, the effects of the ET axis may be autocrine or endocrine. 
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THERAPEUTIC AGENTS 
   Endothelin-receptor antagonists  
As the diseases for which endothelin-receptor antagonists are targeted for therapy are 
chronic diseases, including hypertensive and fibrogenic disorders, requesting drug intake 
once or sometimes twice a day for many years, oral bioavailability is required for patient 
compliance to their treatment. Due to the nanomolar/picomolar IC50 values of ET-1 binding 
to its cognate receptors, receptor antagonists have to be of low nanomolar affinity. Thus, the 
molecules developed as therapeutic endothelin-receptor antagonists must have these two 
properties, oral bioavailability and high affinity. Many research groups have begun work on 
the discovery and development of endothelin-receptor antagonists for the treatment of such 
diseases. Many synthetic molecules have been designed, prepared and evaluated, first in in 
vitro cellular models, then in in vivo experimental animal models of human diseases, and 
finally, for some of them, in human clinical trials. Whereas some compounds are being 
marketed to treat pulmonary arterial hypertension (PAH), several other compounds have been 
evaluated in late clinical trials for various indications. The compounds were generally active 
at low nanomolar concentrations and orally bioavailable. They were designed to be either 
ETA-selective antagonists (Table 1) with selectivity ETA/ETB>100, or dual ETA/ETB 
antagonists (Table 2) with selectivity ETA~ETB, whereas very few ETB-selective antagonists 
(Table 3) with selectivity ETA/ETB<100 have been developed and evaluated in clinical trials. 
Only two types of endothelin-receptor antagonists have reached clinical use: ETA-selective 
and dual antagonists; however, at high concentrations, ETA-selective antagonists may display 
dual antagonistic properties for ETA/ETB.  
  Side effects 
  The side effects linked to this class of therapeutics, mainly studied for sitaxsentan (1),42 
bosentan (2) 43,44 and ambrisentan (3),45 are dual, either drug-related side effects, such as drug-
drug interaction or liver toxicity, or target-related, such as fluid retention or teratogenicity. 
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Liver toxicity is the major side effect of endothelin-receptor antagonists, involving two main 
biological processes. Endothelin-receptor antagonists inhibit the canalicular bile salt export 
pump which translate in a dose-dependent increase of liver enzymes, leading to dose 
adjustment or discontinuation of the treatment. For 2,43,44 elevation of transaminases is 
observed in approximately 10% of patients under the standard 125-mg bid regimen. In 
contrast to 1, elevation of liver enzymes is usually reversible when 2 is discontinued. The 
regulatory agencies recommend a monthly control of liver enzymes for patients treated with 
2. Liver toxicity appears to be less frequent with 3,45 occurring in 1 to 5% of patients. A more 
severe and sometimes irreversible liver toxicity is also encountered; its severity and incidence 
vary, however, with each compound; after three cases of irreversible and fatal liver failure 
under 1,42 published in 2009 and 2010, Pfizer decided to withdraw this drug from the market 
in 2010. Another common side effect and problematic drawback of endothelin-receptor 
antagonists is fluid retention. This side effect is mediated by the ETA receptor and is due to a 
direct effect of this class of drugs on the renal collecting duct. It is partially related to the 
vascular action of the drugs and does not arise from alterations in cardiac function, according 
to animal studies. This side effect is more frequent with 2, occurring in 10 to 20% of cases, 
depending on the daily dose. Older patients are more likely than younger patients to suffer 
from this side effect. All endothelin-receptor antagonists are teratogenic; therefore, 
administration to women with child-bearing potential should be accompanied by expert 
contraception counseling. Drug interactions may also occur. Compound 2 is metabolized by 
cytochrome P450, CYP2C9 and CYP3A4, and numerous drug interactions have been 
described. Among the most clinically relevant are a decrease in estrogens and progesterone 
levels for oral contraception, a decrease in sildenafil levels with concomitant administration, a 
rise in 2 blood levels with HIV-protease inhibitors, a decrease in the efficacy of 
anticoagulation with anti-vitamin K agents such as warfarin. Drug interactions are less severe 
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and less prevalent with 3 and macitentan (4).46,47 
   Molecules developed for therapeutic purposes 
Several previous reviews have described the clinical characteristics of endothelin-receptor 
antagonists, the “sentan” family of drugs24-28,48. Thus, this information will not be discussed 
in detail in this Perspective. Only brief comments concerning some selected compounds are 
provided here, in particular concerning the biochemical characteristics of the most recently 
approved dual ETA/ETB endothelin-receptor antagonist 4. The detailed clinical information is 
provided in the dedicated sections below. Several ETA-specific endothelin-receptor 
antagonists have reached human clinical evaluation for diseases such as PAH, cancer or 
kidney diseases,49-52 including 1, 3, atrasentan (5),24,53, clazosentan (6),54 zibosentan (7),27,55 
which are discussed below.  
 
Table 1: ETA-selective antagonists.  
 
name   structure  comment     company      reference 
___________________________________________________________________________ 
1 sitaxsentan        ETA/ETB: 6000x   Pfizer   42  
Thelin 
 
 
___________________________________________________________________________ 
3 ambrisentan       Gilead/            45 
Letairis (USA)       GlaxoSmithKlein 
Volibris (EU) 
(LU-208075) 
O
COOH
O
N
N
 
OO
S
S
N
H
NO
Cl
O OO
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___________________________________________________________________________ 
 
5 atrasentan     IC50: 0.055 nM   Abbott      24,53 
ABT-627 
Xinlay 
___________________________________________________________________________ 
6 clazosentan      ETA/ETB: 1000x       Actelion  54 
RO-61-1790 
AXV-034343 
 
__________________________________________________________________________ 
7 zibotentan    AstraZeneca       27,55 
ZD4054      
 
___________________________________________________________________________ 
8 BQ123             56 
    
        
                             
___________________________________________________________________________ 
9 avosentan                       Speedel            57 
SPP301 N
S
NH
N
N
N
O
OMe
OMe
O O
 
N S
N+Na-
N
N
N
O
OMe
O
OH
O O
N
N N
N+Na-
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___________________________________________________________________________ 
10 darusentan dual/ETA-selective     Gilead   58    
LU-135252 
HMR-4005 
___________________________________________________________________________ 
11 edonentan   Bristol-Myers-Squibb        59 
BMS 207940 
 
___________________________________________________________________________ 
12 nebentan          Astellas Pharma 60 
YM-598 
 
 
___________________________________________________________________________ 
13 RO-462005  ETA/ETB: 1000x Hoffmann-La Roche  61,62 
   
 
 
__________________________________________________________________________ 
 
The dual ETA/ETB antagonist 243,44 was the first molecule approved for clinical use; 
N
H
N
N
N
N
O
O
O
S
O O
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however, clinical trials rapidly revealed that 2 tended to induce liver toxicity. Structural 
modification of 2 produced 4,46,47 which has improved an toxicity profile and biological 
characteristics and is presently approved for clinical treatment of PAH.47,48,63,64 Minimal 
accumulation of 4 in the liver suggests that it will be less prone to drug-drug interaction than 
2, an advantage for combination therapies necessary in cancer treatment.65 The interaction 
profile of 4 in vitro has shown it is also an inhibitor of the drug-resistance molecule P-
Glycoprotein (P-Gp), as well as of other proteins involved in cancer chemoresistance, which 
may enhance its anti-cancer properties, in particular for multidrug-resistant cancers (see 
below). A comparison of the biochemical characteristics of 2 and 4 is also of interest. 
Molecular-homology docking of 2 on ETB showed the involvement and importance of 
Arg82, Arg84 and His197 in hydrogen bonding between the antagonist and ETB.66 
Compound 4 shows slow apparent ETA-receptor association kinetics, consistent with a 
competitive mode. 2 and structurally related molecules are characterized by fast dissociation 
kinetics and very short (~1 min) occupancy half-lives at ETA, whereas 4 and structurally 
related molecules display a 20-fold slower dissociation half-life, resulting in insurmountable 
antagonism. The interaction of 4 with ETA depends predominantly on hydrophobic 
interaction, not on charge-charge interactions, and the tightly packed conformation adopted 
by 4 fits into a defined pocket of ETA, in contrast to the non-compacted structure of 2. 
Mutagenesis studies showed that Arg326 and Ile355 are important for 2 but not 4, binding to 
ETA. The opposite is true for Leu322.67,68  
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Table 2: dual ETA/ETB antagonists. 
 
name   structure  IC50 /ETA/ETB      company      reference 
___________________________________________________________________________ 
2 bosentan       ETA: 45 nM  Actelion      43,44 
Tracleer     ETB: 202 nM 
RO470203 
 
___________________________________________________________________________ 
4 macitentan         ETA: 0.5 nM Actelion       46,47 
Opsumit         ETB: 391 nM 
    
 
 
___________________________________________________________________________ 
10 darusentan    dual/ETA-selective Gilead        58    
LU-135252 
HMR-4005 
 
__________________________________________________________________________ 
14 TAK-044            Takeda        69  
 
 
    
 
S
NH
N
N
O
O
OH
O
t-Bu
O O
N
N
 
O
COOH
O
N
O
O  
HN
N
H
H
N N
NO
O OHN
N
H
H
N
O O
S
O
COONa
O
COONa
 
N
H
S
NH
N
N
O O
O
O
N
N
Br
Br  
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___________________________________________________________________________ 
15 tezosentan   Actelion       70 
 
 
___________________________________________________________________________ 
16 T-0201      ETA: 0.4 nM  Tanabe       71 
      ETB: 12 nM 
 
 
 
___________________________________________________________________________ 
17 SB209670           72    
        
        
       
 
  
__________________________________________________________________________ 
18 enrasentan                   73 
SB217242  
___________________________________________________________________________ 
HO
S
NH
N
N O
O
O O
N
N
Br 
O
O
O
O
O
OH
O
OH
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   ETB-selective antagonists, exemplified by BQ78823 (19), have mostly been used in 
preclinical cellular and animal experimental models. 
 
Table 3: ETB-selective antagonists. 
name   structure   IC50: ETA/ETB            reference 
___________________________________________________________________________ 
19 BQ788  ETB: 1.2 nM           23 
                       ETA: 1300 nM    
 
___________________________________________________________________________ 
20 A192621                  74 
 
 
 
 
___________________________________________________________________________ 
21 IRL2500   ETA: 94 nM        75 
      ETB: 1.3 nM   
        
___________________________________________________________________________ 
22 RES7011   peptide-based molecule               76 
 
N
H
N
N
H
H
N COONa
O
O
O
N
O
O
 
O
O
N
HO
O
NH
CH3
H3C
H3C
O
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cyclo(Gly-Asn-Trp-His-Gly-Thr-Ala-Pro-Asp)-Trp-Phe-Phe-Asn-Tyr-Tyr-Trp 
___________________________________________________________________________ 
23RO-468443          77 
          
 
_________________________________________________________________________ 
 
Inspired by the structure of the molecules developed early in experimentation, novel series 
of endothelin-receptor antagonists have been designed and evaluated. A few examples are 
shown in Scheme 1. Compound 2478: this series is based on a 1,3,4,5-tetrahydro-1H-benzo[e] 
[1,4] diazepin-2-one scaffold producing derivatives that are potent dual ETA/ETB receptor 
antagonists with affinities in the low-nanomolar range. Compound 2579: this series of ETA-
selective receptor antagonists has a 2H-chromene skeleton and is based on a series of 
angiotensin-II receptor 1 (AT1) antagonists. The most potent compound binds to the ETA with 
an IC50 value of 0.19 nM and is 630-fold selective for ETA compared to ETB. Compound 2680: 
based on the ETA-selective antagonist (S)-3-methoxy-2-(4,6-dimethoxypyrimidin-2-yloxy)-
3,3-diphenyl propionic acid (LU 135252); structural modifications resulted in the antagonist 
(S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenyl-
propionic acid (LU 302872), with a Ki = 2.15 nM for ETA and a Ki = 4.75 nM for ETB. 
Compound 2781: a series of 1,3,6-trisubsituted-4-oxo-1,4-dihyroquinoline-2-carboxylic acid 
analogs were prepared as ETA-selective antagonists, with the most potent displaying an 
IC50 = 0.11 nM and a ETB/ETA selectivity of > 8000x. Compound 2882: a series of novel 2-
[(4,6-dimethylpyrimidin-2-yl)oxy]-3,3-diphenyl butyric-acid derivatives were synthesized and 
O
O
N
N
O
HO
HO
HN
S
O
O
O
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evaluated, with the most potent displaying potency comparable to that of 2. 
 
         
         24    25     26 
 
                                                 
27       28 
Scheme 1. Examples of endothelin-receptor antagonists based on chemical modifications of 
previously developed compounds. 
 
Approaches other than modifying previously developed compounds have also been 
attempted. For example, inhibition of ET-1 precursor activation by ECE-1 (EC 3.4.24.71) 
may be an alternative to using receptor antagonists. A series of non-peptidic thiol-based ECE-
1 inhibitors were able to inhibit DNA synthesis in human GBM cells. This effect was not 
reversed by exogenous addition of ET-1, suggesting an intracellular effect of ECE-1 inhibitors 
not involving extracellular production of ET-1.13 Receptor-specific antibodies may also 
represent an alternative to synthetic compounds as endothelin-receptor antagonists. In 
melanoma cell lines, the binding characteristics of a monoclonal antibody (mAb) developed 
against tumor-specific epitopes of ETB, possibly N-terminal truncation at Arg64-Ser65 by 
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ligand-induced hydrolysis by a metalloprotease, suggest other therapeutic possibilities. This 
hydrolytic truncation was also shown to abolish ETB-mediated EGFR transactivation.83 
 
CLINICAL TRIALS 
   Clinical trials of endothelin-receptor(s) antagonists in human diseases.  
   Endothelin-receptor antagonists in cardiovascular diseases other than PAH 
We have previously reviewed in detail clinical trials performed before 2009.84 In this 
section, therefore, we will summarize only the main results of these early trials. We will 
present the more recent trials, in particular clinical trials for PAH and development of the dual 
ETA/ETB antagonist 4 for PAH, cancer and fibrosis, in more detail. Antagonists of ETA or 
ETB and inhibitors of ECE-1 were initially developed for the treatment of cardiovascular 
diseases. The first antagonists to be tested in healthy human volunteers and patients with 
chronic heart failure (CHF) were peptidomimetics, the ETA-selective BQ12356 (8) and the 
ETB-selective BQ78823 (19). The usual problems of peptide-like molecules, such as poor 
bioavailability and susceptibility to proteolytic enzymes, arose, but these trials were very 
useful in defining the physiological functions of ET-1 in health and disease. The information 
gained85,86 suggested that ET-1 maintains vascular tone via basal activation of ETA on 
vascular smooth-muscle cells, whereas ETB activation reduces basal vascular tone and 
vasodilatation, which are mediated by nitric oxide (NO) generation in the endothelium. 
Patients with hypertension responded to infusion of 8 and 19 with more vasodilatation than 
did healthy subjects. Additionally, ETA-selective antagonists, but not dual ETA/ETB 
antagonists, improved hypertension. In animal models, dual or ETA-selective antagonism 
ameliorated left-ventricular functions, prevented ventricular remodeling and resulted in 
prolonged survival, properties not shared by ETB antagonists. Altogether, the information 
obtained from these early molecules suggested an advantage in the treatment of 
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cardiovascular disease to the development of non-peptidomimetic antagonists to modulate the 
functions of ET-1 receptors. Therefore, low-molecular-weight synthetic ETA-selective or dual 
ETA/ETB antagonists, but only very few ETB-selective antagonists, were developed and 
evaluated in clinical trials. From the published results of these early clinical trials, it can be 
inferred that the endothelin axis, in addition to regulating vascular tone, may also promote 
vascular-cell migration, proliferation, differentiation and/or growth. In patients with CHF, 
ETA blockade was more favorable than ETB blockade; however, in the long-term, a lack of 
beneficial effects of endothelin-receptor antagonists in heart failure mortality/morbidity was 
observed.87 The results of these trials did not meet expectations for CHF patients; however, 
some encouraging information was obtained for patients with primary and secondary PAH.  
Due to its inherent ability to produce potent and prolonged vasoconstriction, ET-1 has been 
postulated to be a critical mediator of cerebral vasospasm. A phase-IIa trial conducted with 
the ETA antagonist 6 demonstrated a benefit for patients in terms of the severity and incidence 
of vasospasm. ETB antagonism, however, may be detrimental due to inhibition of ETB-
mediated NO production, as was observed for the dual ETA/ETB antagonist TAK-044 (14).69  
   Endothelin-receptor antagonists for the treatment of PAH 
PAH is a pathological lung condition arising from multiple etiological causes leading to 
vascular remodeling, an abnormal thickening of the arterial wall and an increase in pulmonary 
vascular resistance. The hemodynamic consequences of PAH are an increased afterload for 
the right ventricle and, eventually, right heart failure and ultimately death. When untreated, 
PAH has a grim prognosis, with a median survival of approximately two to four years from 
diagnosis. The basic defect in the pathogenesis of PAH is thought to be an endothelial 
dysfunction with impaired paracrine signaling from endothelial to smooth-muscle cells.88 A 
number of biological systems have been implicated, including increased ET-1 expression in 
vascular endothelial cells from human pulmonary arteries.88,89 Three therapeutics are 
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presently registered with the FDA (US Federal Drug Administration) and/or the EMA 
(European Medicines Agency) for the treatment of PAH. The first endothelin-receptor 
antagonist, the dual ETA/ETB antagonist 244 was approved in USA in 2001 and Europe in 
2002.  Then the ETA-selective antagonists 142 and 345 were approved, respectively, in 2006 by 
EMA and in 2007 by FDA, and in 2008 only by EMA, followed by the dual ETA/ETB 
antagonist 4,46,47 approved by both institutions in 2013. Compound 1 has been withdrawn by 
Pfizer in 2010. 
The potential advantage of selective ETA antagonism over dual ETA/ETB blockade remains 
controversial in the field of PAH.90 Physiologically, ETB mediates vasodilatation through the 
NO pathway, and it may appear counterproductive to inhibit that pathway; however, in 
pathological states, cross-talk between ETA and ETB may occur with heterodimerization of 
both types of receptors. Under these conditions, ETB may also mediate vasoconstriction91 and 
proliferation of smooth-muscle cells.92 As there has been to date no direct comparison of both 
classes of antagonists in a randomized and blinded trial, there is no formal evidence for 
clinical use. While ET-1 receptor antagonists have been demonstrated to be clinically useful 
in PAH, their use as a monotherapy is often insufficient to lastingly relieve symptoms in 
affected patients, suggesting the value of combination-therapy regimens, which are presently 
under evaluation.  
For the present review, the databases PubMed (www.ncbi.nlm.nih.gov/pubmed), the NIH 
registry for clinical trials (clinicaltrials.gov), the WHO international clinical trials platform 
(http://apps.who.int/trialsearch) and reviews from the last five years93-95 were consulted. In 
particular, the systematic review by the Cochrane collaboration published in 201396 remains 
of high interest, as it included and analyzed all but three trials available to date. Fourteen 
studies were identified according to the search criteria: four for 3, six for 2, three for 1 and 
one for 4. These studies are summarized in Table 4. 
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Table 4. Clinical trials of endothelin-receptor antagonists for patients with PAH. 
 
Drug  dose  code trial        comparator   duration patients    outcome 
          [mg]             [weeks] 
__________________________________________________________________________ 
1    100/300 STRIDE-197   placebo 12 untreated   increased peak VO2 
       50/100 STRIDE-298   placebo 18 untreated   improved 6-MDW 
      2  18 untreated  6-MWD neutral 
 
       50/100 STRIDE-499   placebo 18 untreated  worsened 6-MWD  
__________________________________________________________________________ 
2   125/250 ASSET-1100   placebo 16  untreated  improved PVR  
        125 Study-351101   placebo 12  untreated  improved 6-MWD 
     125/250 BREATHE-144 placebo 16  untreated  improved 6-MWD 
     125 bid BREATHE-2102 epoprostanol16  untreated  Neutral PVR 
     125 bid BREATHE-5103  placebo 16  untreated  improved PVR 
     125 bid COMPASS-2104placebo >16 sildenafil  neutral TCW 
     125 bid EARLY105   24 untreated NYHA II decreased PVR 
          neutral 6-MWD 
 
     125 bid SERAPH106   sildenafil 16 untreated   no arm difference 
__________________________________________________________________________ 
3     5/10 ARIES-1107   placebo 12  untreated   improved 6-MWD 
       2.5/5 ARIES-2107   placebo 16  untreated   improved 6-MWD 
         5  ATHENA-1   none and 24 PDEVi   improved 6-MWD  
  PVR compared to baseline 
10 AMBITION108  sildenafil >24 untreated  no arm difference in 
         TCW  
__________________________________________________________________________ 
4    3/10  SERAPHIN47   placebo 115 untreated  improved TCW 
        10     placebo 115 PDEVi or prost. improved TCW 
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__________________________________________________________________________ 
6-MWD: 6 min walking distance; PVR: pulmonary vascular resistance; Peak VO2: maximal 
oxygen consumption on exercise; TCW: time to clinical worsening; PDEVi: 
phosphodiesterase V inhibitor; RV: right ventricle; Prost: prostanoids.  
 
In previously untreated patients, all studies but one yielded a positive primary outcome. The 
earlier trials were of short duration (12-16 weeks) and used mainly the distance achieved 
during the six-minute walking test (6-MWD) as the primary outcome.109,110 Only the 
STRIDE-4 study yielded a negative result in patients treated with 50 mg 1. The gain was also 
modest in the SERAPHIN study, but 63% of the patients included in this study had already 
been treated, mostly with phosphodiesterase-V (PDEV) inhibitors. The short duration of most 
studies was also criticized by experts and regulatory agencies.111 For these reasons, more 
recent trials have been designed with a new composite primary index: time to clinical 
worsening (TCW). The two most recent studies that applied this new primary outcome 
(SERAPHIN and AMBITION) were also of longer duration and included significantly more 
patients than the earlier studies. Most studies have published data on the improvement in 
symptoms and mortality (Reveal registry).112 Overall, one half to two thirds of patients did not 
worsen, while the remaining improved.  
The most recently approved antagonist 4 has been studied in SERAPHIN,47 a multicenter, 
double-blind, placebo-controlled, parallel-group, event-driven, phase-III outcome study 
involving 742 patients with symptomatic PAH randomized to three treatment groups 
(placebo, 3 mg or 10 mg 4 once daily) to assess the long-term effects on morbidity and 
mortality. Treatment with 10 mg 4 resulted in a sustained 45% relative risk reduction early in 
treatment. The efficacy of 10 mg 4 on the primary endpoint was consistent across subgroups 
of age, sex, ethnic origin, geographical region, etiology, monotherapy and combination with 
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another PAH therapy. The majority of adverse reactions were mild to moderate in intensity. 
Therefore, 4 was approved in 2013 by the FDA and the EU Commission as an orally available 
dual ETA/ETB antagonist for the treatment of PAH.  
   While earlier studies compared essentially single-drug regimens with a placebo, three more 
recent trials included patients already treated with a drug of another therapeutic class, such as 
PDEV inhibitors or prostanoids (Table 4). Not surprisingly, positive results are more difficult 
to demonstrate for this group than for treatment-naive patients. Only the study with 4 10 mg 
which included a large number of patients for an extended period of time was able to show a 
benefit of adding an endothelin-receptor antagonist to a preexisting PAH therapy.47 The 
design of the AMBITION study was different, as 3 and tadalafil were introduced together, not 
sequentially. This simultaneous double therapy proved superior to single-drug therapy in 
terms of TCW.108 Based on this latter study, the most recent guidelines advocate the 
concurrent use of a dual-drug regimen while also offering the possibility of starting with a 
single-drug regimen, as not every drug combination has been tested in randomized clinical 
trials (RCT).113  
   It comes as no surprise that pharmaceutical companies have avoided direct comparison of 
their product with other available drugs; only very few investigator-driven comparative 
studies are available. It was not the design of the AMBITION study to compare the two 
single-drug arms (tadalafil and 3). Nevertheless, the TCW was similar in these two groups in 
patients of comparable PAH severity (Table 4). Another study has compared two endothelin-
receptor antagonists, 1 and 2.98 No difference was found in the 6-MWD, the primary outcome 
of this trial. Overall, no striking difference in efficacy was observed among the four 
endothelin-receptor antagonists tested in PAH. 
None of the fourteen RCT performed with endothelin-receptor antagonists in PAH had 
death as the primary outcome; however, deaths were duly recorded in every study. These data 
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showed a trend for less deaths in patients treated with endothelin-receptor antagonists 
compared to placebo.112 The Cochrane review published in 2013 concluded that “there is 
uncertainty as to whether endothelin-receptor antagonists reduce mortality in this 
population”.96 The two most recent trials, SERAPHIN and AMBITION, analyzed morbidity 
and mortality in PAH; however, as non-fatal events define the end of study for the participant, 
it is logical that mortality was not different between the treated and placebo arms in both 
studies.47,108 Finally, as more than eight substances have proven efficacy for PAH it is 
becoming unethical to perform placebo-controlled studies, especially with mortality as the 
major endpoint. 
In conclusion, the three clinically available oral endothelin-receptor antagonists are 
considered as first-line therapies for PAH functional class II and III, intravenous epoprostenol 
being the first choice for patients in class IV.113 According to the AMBITION study, 
concurrent therapy with 3 and tadalafil is also recommended as a first-line treatment. In case 
of unsatisfactory response to a single-drug regimen, sequential use of a double- or triple-drug 
regimen is proposed.  
Several studies with 3 and 4 are presently ongoing (Table 5). These trials address mainly 
specific subtypes of PAH, such as Eisenmenger syndrome or portopulmonary hypertension. In 
addition, some trials explore the benefit of endothelin-receptor antagonists in other PAH 
groups such as PAH due to left heart disease or inoperable chronic thromboembolic 
pulmonary hypertension.114 
 
Table 5. Ongoing studies of endothelin-receptor antagonists. 
study and NCT No drug target primary outcome 
ATPAHSS 
NCT01042158 
3, 10 mg 
+/- sildenafil 
Scleroderma-associated 
PAH 
6-MWD 
Published 09.2015 
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NCT02253394 3, 10 mg 
+/- spironolactone 
PAH 6-MWD 
MAESTRO 
NCT01743001 
4, 10 mg Eisenmenger syndrome 6-MWD 
MELODY 
NCT02070991 
4, 10 mg Pulmonary hypertension 
due to left heart disease 
Hemodynamics 
MERIT 
NCT02060721 
4, 10 mg Chronic thromboembolic 
pulmonary hypertension 
6-MWD 
PORTICO 
NCT02382016 
4, 10 mg portopulmonary 
hypertension 
PVR 
SCOBA-PH) 
NCT01330108 
Switch 2, to 3, 
10 mg 
PAH Safety, Six-MWD 
6-MWD: 6 min walking distance; PVR: pulmonary vascular resistance.  
 
In summary, endothelin-receptor antagonists of both ETA-selective and dual ETA/ETB 
subtypes have shown clinical interest and benefit for patients with PAH; however, even if 
these therapeutics can delay disease progression, they are not curative. 
 
   The functions of the endothelin axis beyond PAH: cancer  
As stated above, ET-1 beside being a potent vasoconstrictor is also an anti-apoptotic and 
mitogenic peptide whose expression, as well as that of the components of the whole 
endothelin axis, is largely increased in human cancers.115-119 Cancer is a proliferative disorder 
of the cancer cells themselves, as well as of the cancer-associated stromal cells, mainly 
endothelial cells and fibroblasts. The transformation of fibroblasts into myofibroblasts is a 
characteristic of not only cancer but also of fibrogenic diseases. In human cancers, depending 
 30 
on the relative expression of ETA and ETB, the endothelin axis may act as a growth-promoting 
or an apoptosis-promoting effector. The main source of ET-1 is the tumor-associated 
endothelium, whereas ET-1 production by human tumor cell lines has also been 
demonstrated.120 Using ex vivo, in vivo and in vitro approaches, the expression of ET-1, ECE-
1a-d, ETA and ETB was determined in human prostate, ovarian, breast, cervix, oral, lung and 
colon carcinoma, GBM, melanoma and Kaposi sarcoma, and the relevant human tumor cells 
in culture.13,39,115,116,121-128 In these human cancers, ETs were survival factors, protecting 
tumor cells against apoptosis.115,116,128,129 From these data, ET-1, ETA and/or ETB-receptors 
have been proposed to be involved in cancer progression. In human cancer samples it was 
generally observed that the ET-1 precursors, ECE-1 and the ETA and/or ETB receptors were 
also expressed by the tumor-associated stroma. Thus, in human cancers, depending on the 
type of cancer, the main source of ETs may be either the cancer cells, mainly in carcinomas, 
or the cancer-associated stroma, including the tumor-associated vasculature, in non-carcinoma 
tumors. Published data indicate that the main endothelin receptor implicated in human 
carcinomas is the ETA receptor, whereas in human GBM and melanoma, it is the ETB-
receptors. The role and the mechanisms of ET-1-mediated effects in cancer have been mainly 
studied in preclinical models and have been previously reviewed in detail by others.123-127,130-
132 Thus, we will not repeat the details of these previous reviews. Only some information 
discussed in previous reviews will be outlined here.  
Preclinical cellular and animal experimental models have implicated all components of the 
endothelin axis in cancer development and progression. ET-1 is a direct cell-proliferation and 
cell-survival factor for cancer cells and is involved in the transactivation of other tumor-cell 
receptors, mainly the EGF receptor. ET-1 also promotes cancer-cell epithelial-to-
mesenchymal transition (EMT), migration, invasion and metastasis, and resistance to 
chemotherapy; however, ET-1 is also involved in the interactions between tumor cells and 
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their environment. ET-1 induces tumor-associated angiogenesis, increasing the release of 
VEGF and stimulating (myo)fibroblasts and cancer cells to produce pro-angiogenic proteases.  
ET-1 mediates the recruitment, proliferation and differentiation of fibroblasts into tumor-
associated myofibroblasts, and the interaction of cancer cells with inflammatory/immune 
cells, pro-tumoral macrophages (type-2 macrophages) and anti-tumoral T-lymphocytes. ET-1 
also upregulates pro-fibrotic growth factors, contraction- and migration-enhancing factors, 
thus favoring the development of tumor stroma.133  
Most preclinical studies of endothelin-receptor antagonists have been conducted in 
experimental models of ovarian and prostate carcinomas.121,123,124,127,132,134 In epithelial 
ovarian cancer cells, a link between an autocrine ET-1/ETA pathway, EGFR and beta-catenin-
beta arrestin-mediated transcriptional activity, EMT, chemoresistance and possibly metastasis 
was proposed.135-138 ET-1 via ETA transactivates EGF receptors in ovarian cancer cells, and 
combination of the ETA antagonist 7 with an EGFR antagonist (gefitinib) strongly reduced 
proliferation and invasion of ovarian tumor cells. In an experimental model of multidrug-
resistant (taxol or cisplatinum) ovarian tumors, 4 in combination, but not alone, was highly 
anti-tumoral, reversing drug resistance, suggesting that drug combination should be 
considered in cancer therapy.139 In a preclinical study of colon cancer, the specific ETA 
antagonist 7 inhibited cell proliferation, but cell migration was more inhibited by an ETB 
antagonist than by an ETA antagonist and cell contraction was more inhibited by combined 
ETA and ETB blockage; however, it has to be emphasized that in vitro, the concentration of 
the antagonists necessary to induce or potentiate apoptosis in cancer cells was much higher 
than the concentrations effective in the context of cardiovascular diseases. These 
concentration-dependent effects resemble the effects observed when modifications were 
introduced in the transmembrane domain 3 and cytoplasmic domain 2 of ET-receptors using 
either mutagenesis or chimeric receptors. Alternatively, the localization of the endothelin 
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receptor(s) is intracellular in tumor cells, rendering them poorly accessible to the antagonists. 
Another explanation may be that endothelin-receptor antagonists are substrates for ATP-
dependent membrane transporters involved in drug resistance, such as P-Gp.  
However, most of these preclinical data, in particular the expression of mainly ETA by 
tumor cells, were established using experimental models of epithelial tumors, the so-called 
“carcinomas”. It was realized only recently that the picture may be different in non-carcinoma 
cancers, the “mesenchymal” tumors. In human non-carcinoma cancer, the pattern of 
expression of endothelin receptors is more complex. For example, we observed that in human 
GBM surgical samples, ETA receptors were mostly expressed by blood vessels, while ETB 
receptors were mainly expressed by the tumor cells. The pro-survival functions of ET-1 for 
GBM and melanoma cells in culture were exerted via the ETB receptor.13,116,140 In GBM cells 
in culture, exogenous ET-1 enhanced tumor-cell migration and MMP-9 and MMP-13 
expression.141 ET-3 is mainly expressed in the central nervous system and has been involved 
via ETB in the progression of GBM via an autocrine pathway in GBM stem cells able to 
maintain their stemness-associated properties. Compound 19, A19262174 (20, Table 3) and 
ET-3 RNA interference blocked growth and induced GBM stem-cell apoptosis. Thus, ETB 
antagonists may be valuable in GBM and oligidendroglioma therapy.142-144  
Interaction with cancer-associated stroma has also been studied. ETA is critical in mediating 
immune-cell recruitment and T-cell-mediated antitumor activity, while ETB is a barrier to this 
recruitment.139 Neither 4 nor the combination of 8 and 19 modified immune-cell recruitment 
to cancer.139 In an experimental model of breast cancer, macrophages were shown to induce 
the endothelin-integrin axis in endothelial cells, favoring the adhesion and migration of breast 
tumor cells across the vascular wall, the early steps of metastasis.145 ET-1 may stimulate the 
growth of fibroblasts and it was shown that in co-culture of ovarian carcinoma cells and 
fibroblasts the growth of both populations was reciprocally stimulated.146 The high rate of 
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binding of ET-1 to (myo)fibroblasts, implicates these cells in tumor progression and ET-1 
receptors as potential therapeutic targets.147 Induction and overexpression of ETB receptors 
was observed in colon cancer-associated (myo)fibroblasts and endothelial cells.115,148 These 
observations were later confirmed in different human cancers, suggesting that tumor cells can 
induce ETB in their stroma. These stroma-expressed ETB can participate in the progression of 
cancer and be relevant targets for therapeutic purposes. In brain cancers, expression of ETA 
was demonstrated in human gliomas and meningiomas, with high affinity for ETA 
antagonists. In human surgical samples from patients with GBM, ET-1, ECE-1 and ETA were 
mainly expressed by GBM neovessels, while ETB is mainly expressed by the tumor cells, 
suggesting that GBM vessels are likely a source of ET-1 acting on cancer cells via ETB. ETA 
was also expressed by tumor-associated vessels. Induction of the ETB-type receptor in tumor 
stroma, mainly in reactive astrocytes and in myofibroblasts ensheathing tumor neovessels in 
GBM,116 indicated that the endothelin axis is also important in the interactions between non-
epithelial human cancers and their stroma. The dual ETA/ETB-antagonist 2 induced apoptosis 
in human GBM cells. ET-1 via ETB is a survival factor but not a proliferation factor for GBM 
cells.111 Meningiomas have been shown to express mainly ETA.149 The ET-1/ETB axis was 
shown to reduce P-Gp functions at the blood-brain barrier (BBB), an important effect for the 
transport of chemotherapeutics in brain cancer, and other cerebral disorders.148 Thus, tumor 
cells can induce ETB in their stroma and stromal ETB can participate in the progression of 
brain cancer and be an additional target of the endothelin axis for therapeutic purposes.  
The endothelin axis was also involved in maintaining the properties of cancer stem cells 
(CSC). Compound 4 alone did not show significant anti-tumor activity, while in combination 
with chemotherapy, 4 demonstrated specific anti-CSC activity. Lack of stromal ETB is 
associated with diminished infiltration of tumor-associated macrophages.151 Endothelin 
receptors also play a permissive role in tumor metastasis, the main cause of mortality of 
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cancer patients. In an experimental murine model, the ET-1/ETA axis was shown to enhance 
lung metastasis of bladder cancer, preceded and depending on macrophage infiltration of the 
lung. Thus, the pro-inflammatory functions of the ET-1 axis are important in the context of 
tumor progression.130  
Antagonists of either ETA, ETB or the combination of both have involved the couple ET-
1/ETA in modulating the functions of cancers in many of these preclinical experiments. 
However, all together the results suggest that in the context of cancer, dual ETA/ETB 
antagonism may be superior to single antagonism. Moreover, many of these beneficial effects 
of blocking the endothelin receptors were observed when the antagonists were applied very 
early in the development of these experimental tumors.  
Other components of the endothelin axis may also be involved in cancer, such as the 
expression of variants of ECE-1 (ECE-1a, ECE-1b, ECE-1c and ECE-1d), variants of the 
receptors, or the ET-2 and/or ET-3. peptides Only limited information exists concerning the 
inhibition of ECE-1 to control the activation of bigET-1 to ET-1.13 It was shown in a murine 
model that germ-line mutations and subsequent promoter hypermethylation of the ETB gene 
and the absence of ETB transcripts may be responsible for susceptibility to cancer.152 
Promoter methylation of the EDNRB gene in gastric cancer and in oral squamous-cell 
carcinoma is correlated with the aggressiveness and progression of the cancer.41,153  
In summary, preclinical experimental cancer models and ex vivo studies suggest that 
malignant cell growth and survival are dependent on ET-1-mediated pathways. Endothelin-
receptor antagonists demonstrated promising effects in the context of experimental cancer as 
molecules with the potential to control survival of tumor cells and regulate vascular functions 
and angiogenesis induced by tumor cells, an important factor in the mechanisms of cancer 
progression. In cancer, ET-1 is not a growth factor by itself, but it appears to potentiate tumor-
cell growth induced by other growth factors such as bFGF, EGF, IGF-I and IGF-II, through a 
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PKC-mediated pathway, involving several intracellular signaling pathways. Antagonists of 
the receptors of the endothelin axis have anti-tumor effects in human cells and in animal 
cancer models, which have been attributed to their direct anti-survival effects on tumor cells 
and/or on the tumor-associated vasculature. Based on promising preclinical results, clinical 
trials in human cancers mostly evaluated the effects of antagonists of ETA; however, while 
ETA is important in tumor-cell migration, metastasis and proliferation, ETB is critical for 
angiogenesis and inhibition of anti-tumor immune-cell recruitment, and possibly also for 
tumor growth and metastasis. Thus, dual ETA/ETB blockade may be a valid strategy, which 
was not taken into account in the design of the early clinical trials. 
   Human clinical trials of endothelin-receptor antagonists in cancer 
The encouraging results of cell and animal experimental models of cancer led to the 
evaluation of the two ETA antagonists 5 and 7154,155 in several human clinical trials (up to 
phase III) for ovarian, prostate, breast, colon, lung, or kidney cancer either alone or in 
combination with cytotoxic drugs. Owing to the observed interactions between endothelin 
receptors and EGFR, combinations of ETA antagonists and EGFR antagonists were also 
attempted. Unfortunately, these clinical trials did not show significant effects on their primary 
end-points, defined as time to progression, onset of metastases and/or overall survival. The 
main conclusions resulting of the most important human clinical trials of endothelin-receptor 
antagonists in human cancer are summarized in Table 10 and discussed below. 
We have previously reviewed in detail the clinical trials performed for cancer indications 
before 2009,84 and others have reviewed in detail the clinical trials performed more 
recently.123,125,127,156,157 Therefore, we will only summarize the main outcomes of these early 
trials. We will present in more detail the most recent trials, in particular the clinical evaluation 
of the dual ETA/ETB antagonist 4 in GBM. 
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Table 10. Some examples of clinical trials of ET-1-receptor(s) antagonists in cancer  
___________________________________________________________________________ 
compound  phase  company   disease     end-points 
___________________________________________________________________________ 
A) ETA-selective antagonists 
___________________________________________________________________________ 
 
5   Abbott       prostate, renal carcinomas, glioma 
___________________________________________________________________________ 
5   II (N=288)      hormone-refractory time to progression 
       prostate cancer bone metastasis 
___________________________________________________________________________ 
5   III (N=942)      non-metastatic time to progression 
       hormone-refractory  
        prostate cancer  
___________________________________________________________________________ 
5   III    metastatic  time to progression 
       hormone-refractory  
        prostate cancer  
___________________________________________________________________________ 
 
7           AstraZenecca   prostate carcinoma 
__________________________________________________________________________ 
7   II (N=312)   hormone-resistant time to progression   
       bone metastatic and survival  
prostate cancer 
___________________________________________________________________________ 
7   III (N=312)   hormone-resistant safety and efficacy  
   ENTHUSEMI   bone metastatic and overall survival  
prostate cancer 
___________________________________________________________________________ 
___________________________________________________________________________ 
B) Dual ETA/ETB antagonists   
___________________________________________________________________________ 
2 and 4  Actelion   melanoma and GBM 
___________________________________________________________________________ 
2   II (N=35)   melanoma safety/tolerability 
   II (N=40)     and disease progression 
___________________________________________________________________________ 
4       GBM  launched December 2011 
         completion October 2017.  
safety and tolerability, 
markers of brain tumors.  
___________________________________________________________________________ 
 
Early clinical trials evaluating the efficacy of endothelin-receptor(s) antagonists in human 
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cancers mostly concentrated on prostate carcinomas and ETA-selective antagonists. ET-1 is 
produced in the normal prostate, and ETB is mainly expressed by prostate luminal epithelial 
cells, whereas ETA is found predominantly in the stromal component of the prostate. ETA 
expression is increased in prostate cancer and is associated with progression and osteoblastic 
bone metastasis,122 whereas ETB may be silenced by methylation of its promoter. The effect 
of ET-1 receptor antagonism in prostate cancer has been evaluated, mainly using 5 (a very 
potent ETA antagonist; Ki=0.034 nM) and 7 (a very selective ETA antagonist). Results of 
these early clinical trials generally demonstrated safety and tolerability but no significant 
improvement in survival or time to disease progression. For the treatment of castration-
resistant prostate cancer, combination therapies based on docetaxel are the standard. 
Following attempts to add endothelin-receptor antagonists, the results for ETA antagonists 
were initially encouraging in pre-clinical assays and early human clinical trials. Drug 
combinations have been attempted in a phase-I/II trial of 5 in combination with paclitaxel, 
docetaxel, carboplatin or liposomal doxorubicin,156-159 demonstrating no differences in 
efficacy and patient survival over standard therapeutic regimens but no added toxicity 
compared to chemotherapeutics. A phase I/II clinical trial of 5 combined with docetaxel in 
patients with hormone-refractory prostate cancer showed that 5 pharmacokinetics was not 
influenced by docetaxel, though docetaxel clearance was increased by concomitant 
administration of 5, suggesting a pharmacokinetic drug-drug interaction. Compound 5 
combined with doxorubicin was evaluated in a phase-I/II trial in patients with platinum-
resistant recurrent ovarian cancer. No obvious toxicity was observed, with some indication of 
prolonged survival in a limited number of patients.160 Phase-III trials have nevertheless been 
launched, combining an ETA antagonist with standard chemotherapeutics, and the results are 
now available. Docetaxel and 5 versus docetaxel and placebo was evaluated in men with 
advanced castration-resistant prostate cancer in a randomized phase-III trial (SWOG 50421). 
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In combination with docetaxel, 5 did not improve overall survival and disease-free survival 
compared to placebo. A phase-III, randomized, placebo-controlled study of docetaxel in 
combination with 7 in patients with metastatic castration-resistant prostate cancer (ENTHUSE 
trial) did not result in any benefit compared to docetaxel alone.161 A large phase-III placebo-
controlled trial evaluating the use of 7 for bone metastasis in patients with castration-resistant 
prostate cancer did not show a statistically significant advantage; however, it has an 
acceptable toxicity profile.155  
In non-carcinoma cancer, 5 has been evaluated in phase I in patients with recurrent GBM. 
No dose-limiting toxicities were observed, but its efficacy was not better than those of other 
cytotoxic regimens.162 Based on data suggesting that endothelin may play a role in the 
pathophysiology of melanoma39,140 and that the dual endothelin-receptor antagonist 2 may 
have anti-tumor activity in human melanoma cells,39 a multicenter, open-label, single-arm, 
prospective, proof-of-concept phase-II study assessed the effects of 2 monotherapy on tumor 
response in patients with stage-IV metastatic melanoma. Among the 35 patients included in 
this study, disease stabilization was observed in six of the 32 patients analyzed. These results 
suggest that 2 might have benefits in disease stabilization in certain patients with metastatic 
melanoma.163 No adverse events were observed. Thus a larger, open-label, single-arm phase-
II trial combining first-line dacarbazine and either 2 or placebo (N=40 patients per group) was 
launched in patients naïve to chemotherapy or immunotherapy for stage-IV metastatic 
cutaneous melanoma. Median time to tumor progression (primary endpoint) was not 
significantly different between the two groups.164 However, some hope of a clinical benefit of 
blocking the endothelin receptors in human cancer was raised by evaluating the newly 
developed dual ETA/ETB antagonist 4. Compound 4 in combination with dose-dense 
temozolomide, a standard chemotherapeutic for GBM therapy, is being evaluated in two 
phase-I/Ib open-label studies in patients with newly diagnosed and recurring GBM (clinical 
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trial NCT01499251. Sponsor: Actelion, start date: December 2011, estimated completion 
date: October 2017; an open-label, single-arm phase-I study to assess safety and tolerability, 
and expression of markers of brain-tumor tissues.). Based on the promising preliminary 
results of these trials, Actelion will approach Health Authorities for further discussions about 
the future development of 4 in new and recurring GBM in a phase-IIb/III study (information 
posted on the Actelion website).  
The deceptive results of most human clinical trials with endothelin-receptor 
antagonists156,165 merit evaluation and discussion. For progression, cancer cells require key 
pathways that influence cell growth and death, cell migration, and the development of a 
vascular network and a permissive environment mainly composed of stromal cells, vascular 
cells, (myo)fibroblasts, and immune/inflammatory cells. These pathways include the 
endothelin axis but also other pathways. Preclinical models have demonstrated that the 
blockade of the endothelin axis may reduce tumor growth, driving the development of 
antagonists of endothelin receptors and their evaluation in human clinical trials for various 
cancers.127 However, in these preclinical models, mainly the ETA-dependent pathways and the 
anti-proliferative effects of antagonists on the carcinoma tumor cells were evaluated. Human 
tumors develop according to a time-frame that is much longer than and very likely very 
different from the time-frame and development of animal experimental tumors. Moreover, 
novel compound are often tested in patients with cancer after one and sometimes two or more 
established therapies have failed, meaning that many compounds, including ET receptor 
antagonists are tested at the later stages of cancer. Thus, the expression of both ETA and ETB 
endothelin receptors might be very different and much more complex in human cancers than 
in experimental models. The type of human tumors (epithelial versus non-epithelial origin) is 
also relevant. It has also been shown that stromal cells, including tumor-associated 
(myo)fibroblasts and macrophages expressing both ETA and ETB, are mandatory for tumor 
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progression in humans. This fact has not been considered in early clinical trials. Therefore, we 
believe, but this reflects only our opinion, that in cancer dual antagonists are more appropriate 
and promising than single antagonists. We also believe that combination therapy with ET 
antagonists are also mandatory. But it has to be kept in mind that patients that failed antitumor 
therapies many times have also developed drug resistance, and would likely failed any 
therapy. Thus in our opinion, ET antagonist must be added early in therapy, in addition to 
standard treatments. 
 
   Endothelin receptor antagonists beyond PAH: fibrotic diseases and inflammation 
In response to tissue injury including wounding, surgery, cancer, or drug-induced injury, the 
repair processes may result in two distinct phenomena: a normal regenerative process, limited 
in time, in which injured cells are replaced by cells of the same type, and a chronic, 
uncontrolled fibrotic process, in which connective tissue replaces normal tissue, associated 
with abnormal deposition of extracellular matrix (ECM). Fibrosis is defined by the 
overgrowth, hardening and scarring of tissues, mainly by activated (myo)fibroblasts, and 
finally in the replacement of normal tissue with permanent scar tissue.166 Myofibroblasts may 
be generated from a variety of cellular sources: resident mesenchymal cells, circulating bone-
marrow-derived fibrocytes, or epithelial and endothelial cells by cell-transition mechanisms. 
Myofibroblasts are activated by a variety of stimuli, including ET-1.167 ET-1 plays a 
fundamental role in the pathogenesis of fibrosis and may be a key mediator of profibrotic 
effects of other agents, such as TGFβ1 which induces ET-1 expression, forming an autocrine 
amplifying loop. ET-1 is chemotactic for cells of the fibroblast lineage and causes fibroblast 
proliferation and ECM accumulation and contraction, mediated by the two ET-1 receptors, 
ETA and ETB, expressed on these cells.115,168 Thus, antagonists of both ET-1 receptors may 
have therapeutic potential to prevent the development of fibrosis. Correspondingly, the dual 
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ET-1 receptor antagonist 2 was shown to decrease collagen-I and -III synthesis by fibroblasts.  
In the lung, fibrosis encompasses a variety of idiopathic disorders characterized by a 
progressive replacement of normal alveolar wall by dense connective tissue that eventually 
prevents normal gas exchange. The endothelin axis may be implicated in the pathogenesis of 
lung fibrosis according to experiments in animal models and immunohistochemistry 
performed on human lung tissue from affected individuals. ET-1 was demonstrated to induce 
α-smooth muscle actin (α-SMA) expression and the myofibroblast phenotype in human lung 
fibroblasts through the ETA-JNK-AP-1 pathway.169 Despite its enormous impact on human 
health, there are currently no approved treatments to cure this disease. Two compounds have 
nevertheless been recently approved for the treatment of idiopathic lung fibrosis, as they 
demonstrated involvement in slowing down the disease: pirfenidone and nintedanib. Based on 
preliminary data, a one-year clinical double-blind and randomized study has been performed 
using 2 versus placebo in 158 patients (Build-1).170,171 The primary endpoint was the exercise 
capacity. This study was negative concerning this primary endpoint. A post hoc analysis 
revealed, however, a positive trend in less severely ill patients for the criteria “TCW or 
death”. Similar findings were published for the Build-2 study that involved patients with lung 
fibrosis secondary to systemic sclerosis. According to these findings, a new randomized 
clinical study has been launched (Build-3)170,171 involving 390 patients with established 
pulmonary fibrosis. A similar three-year phase-III study was launched in early 2009 with the 
ETA-selective antagonist 3 (Artemis study). A phase-II study (MUSIC) evaluated 4 for the 
treatment of idiopathic pulmonary fibrosis.172 These studies evaluated TCW as the primary 
endpoint. Unfortunately, all studies produced negative results, the Artemis study being 
prematurely stopped due to an increased progression of the disease in the treated arm. 
Within the kidney, injury to glomerular or tubular cells is the initiating cause of many acute 
and chronic diseases, leading to progressive dysfunction and end-stage renal disease. The 
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glomerulus is the main filtration barrier that determines global kidney function. Inflammatory 
and non-inflammatory stresses affect the glomerulus and lead to alterations in its structure and 
thus, in its permeability and functions, resulting in chronic kidney disease (CKD). In 
hypertension, diabetes and other kidney diseases, the standard treatment is angiotensin II 
antagonism; however, this treatment only modestly slows disease progression. ET-1 via ETA 
activation has also been implicated, in addition to the renin-angiotensin system, in the 
pathophysiology of CKD and particularly in diabetic nephropathy. Animal models have 
shown beneficial effects of the blockade of the endothelin axis on proteinuria and kidney 
functions. ET-1 is the major isoform of the endothelin peptides in the kidney, regulating 
sodium and water excretion, and the vast majority of endothelin receptors of renal cells are of 
the ETB subtype, in contrast to most peripheral organs. Smooth muscle cells of the renal 
vasculature mainly express ETA, while the endothelium express ETB, stimulating the release 
of vasodilators. Most of the dilatory effects of ET-1, as well as vasoconstriction, mesangial 
cell proliferation and inflammation mainly occur via ETA; thus, selective ETA blockade may 
be more beneficial in renal disease, and dual antagonists may block the beneficial 
vasodilatory effects of ETB, causing sodium retention.173,174 Thus, in the diseased kidney, ET-
1-promoting effects on renal cell injury, proteinuria, glomerulosclerosis, inflammation, 
fibrosis and hypertrophy associated with CKD are mainly mediated by ETA.  
Preclinical models of CKD and of type-I and type-II diabetic nephropathy have suggested 
that endothelin-receptor antagonists may be of therapeutic interest in renal diseases. In 
particular, ETA antagonists have been shown to improve renal injury and fibrosis, and this 
possibility has been evaluated in clinical trials.173,174 A phase-II study with the dual ETA/ETB 
antagonist 14 has revealed favorable systemic hemodynamic effects with a trend toward 
increased renal plasma flow in seven patients. A phase-III study with the ETA selective 
antagonist 9,57 performed in 286 patients with diabetic nephropathy and already taking 
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angiotensin blockers showed that albuminuria decreased significantly in the 9-treated group 
compared to placebo. The ASCEND trial testing 9 versus placebo in patients with type-II 
diabetes and nephropathy has been prematurely terminated due to an increase in congestive 
heart failure events and mortality in the 9 arm. The RADAR phase-II study evaluating 5 for 
albuminuria reduction in patients with type-II diabetes and nephropathy showed some positive 
outcomes without obvious edema.51 Completed and ongoing clinical trials for endothelin-
receptor antagonists are summarized in Table 7 (adapted from 174). 
 
Table 7. Completed and ongoing clinical trials for endothelin-receptor antagonists for kidney 
diseases. (adapted from 174) 
 
drug study phase/  disease      end-points and outcome 
 N patients 
___________________________________________________________________________ 
8 N=22   non-diabetic CKD    reduced proteinuria 
___________________________________________________________________________ 
14 N=7   non-diabetic CKD    tendency to increased renal blood flow 
___________________________________________________________________________ 
9 phase II N=286 diabetic nephropathy    modified albumin/creatinine ratio  
          dose-dependent 
 
 phase III (ASCEND) diabetic nephropathy    reduced albumin/creatinine ratio 
 N=1392        in the long-term 
 
1  phase II N=27  non-diabetic CKD    reduced proteinuria better  
          than nifedipine 
___________________________________________________________________________ 
5 phase IIa N=89 diabetic nephropathy    reduced albumin/creatinine ratio 
         
 
 phase IIb (RADAR) diabetic nephropathy    reduced albumin/creatinine ratio 
 N=211       
 
Phase III (SONAR) diabetic nephropathy    primary endpoint: time to  
N=4150 (planed)       serum creatinine doubling 
___________________________________________________________________________ 
 
In summary, the outcomes of preclinical and early clinical phase-II trials suggest that ETA 
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antagonists may be of therapeutic interest and benefit in patients with kidney diseases, the 
main side effects being fluid retention, which may be minimized by careful drug dosing and 
the use of diuretics.174 This information has yet to be confirmed in large multicenter phase-III 
trials. As several studies suggested an interest in the antagonists of the endothelin axis in these 
disorders in addition to the renin-angiotensin system, dual angiotensin receptor type 1 
(AT1)/ETA antagonist were also designed and evaluated in preclinical setting only. Combining 
key structural elements present in an AT1 receptor antagonist (irbesartan, structure not 
disclosed) with structural elements in a biphenylsulfonamide ETA receptor antagonist 
provided compound 29175 which potently blocked both AT1 and ETA receptors, with improved 
pharmacokinetic properties and efficacy compared to AT1 or ETA receptor antagonists 
alone.175 Another dual angiotensin receptor type 1 (AT1, IC50=8.5 nM)/ETA (IC50=8.9 nM) 
antagonist, compound 30,176 was designed and evaluated in a rodent model, showing 
increased potency compared to losartan (a standard AT1 antagonist in clinical use) without 
detrimental effects on heart rate.176 However, to the best of our knowledge, no clinical trial 
has been launched with these dual antagonists. (Scheme 2) 
                             
                   29       30 
Scheme 2: Dual angiotensin type-1 (AT1R) and ETA receptors antagonists. 
 
   Other potential clinical indications for endothelin-receptor antagonists 
Compound 8 or the combination of 8 and 19 are presently being evaluated in a clinical trial 
(NCT02062346, start date: April 2014, completion: March 2017) in patients with vasculitis. 
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The CONSCIOUS-3 phase-III clinical trial assessed the efficacy of 5 in patients with 
aneurysmal subarachnoid hemorrhage, improving vasospasm-related morbidity and 
mortality.177 In an experimental model of arthritis, 2 was shown to have a beneficial effect. 
The results suggested that the detrimental effects of the endothelin axis in arthritis were 
mediated by TNF-α.178 ETs have immunomodulatory properties as pro-inflammatory 
cytokines and inducers of leukocyte adhesion molecules and have been involved in sepsis. In 
an experimental model of LPS-induced lung injury, an ETA antagonist reduced neutrophil 
recruitment and lung injury. Endothelin receptor antagonists may be useful as an adjunctive 
therapy for preserving the organs during infectious diseases.179 In Crohn’ disease, ECE-1, 
ETA and ETB are key players of the inflammatory and fibrogenic process, in particular 
involving the submucosal smooth muscle proliferation.180 In inflammation and sepsis, 
blockage of both endothelin receptors attenuated the inflammatory responses.181,182 However, 
very few clinical trials have evaluated these possibilities, which will not be discussed further 
in the present Perspective. 
 
CONCLUSIONS AND PERSPECTIVES  
The selective expression of the components of the endothelin axis in human diseases has 
been demonstrated, and some information has emerged suggesting that targeting specific 
components of this axis may be of therapeutic interest in human diseases. Within five years of 
the discovery of the endothelin axis, orally available endothelin-receptor antagonists became 
available, and their effects were first evaluated in human clinical trials in the context of 
cardiovascular diseases, heart failure, PAH, resistant arterial hypertension, stroke, 
subarachnoid hemorrhage, then for kidney diseases and various cancers. They were of 
greatest interest for the treatment of PAH and are now in clinical use for this indication. The 
results of most clinical trials for other indications were either neutral or negative, leading to 
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the discontinuation of endothelin-receptor antagonist programs in many but not all 
pharmaceutical companies. Several clinical reviews have analyzed the causes of the failures 
of clinical trials,25,121,123,131,156,183-185 some of which may raise further questions about the 
therapeutic value of endothelin-receptor antagonists.  
Since the very initial stages of development of antagonists of ET-1 receptors, there has been 
a debate about whether blocking ETA selectively, or whether additional blocking of ETB with 
dual ETA/ETB antagonists would be an optimal therapeutic option. ETB-selective antagonists 
were rapidly eliminated from development programs due to side effects. Thus, the debate no 
longer concerns the usefulness of antagonists of endothelin receptors in human pathologies. 
Instead, it is concerned with whether ETA-selective or dual ETA/ETB blockers should be used. 
It is therefore of importance to consider not only receptor selectivity (ETA-, ETB- or dual 
selectivity) but also the particular disease involved when developing new antagonists.  
The selectivity profile of the ideal endothelin-receptor antagonist depends on the clinical 
indications, the organs and the type of cells involved in the disease, the stage of progression 
of the disease and the therapeutic context. Of utmost importance, the heterogeneity of human 
chronic diseases which develop over long-term must be considered, on the contrary of acute 
experimental animal models. In PAH, presently, ETA-selective and dual ETA/ETB antagonists 
have been approved, and it was not possible to identify a clinically relevant advantage for one 
class of drug or the other in this context. However, it was observed in clinical trials for PAH 
that the ETA-selective drug 3 induced more fluid retention than the dual ETA/ETB compounds 
2 or 4. In fibrosis-related disorders, the evaluation of the clinical interest of endothelin 
receptor(s) antagonists has been only very recently initiated, and more feed-back is necessary 
to reach conclusive information; however, human clinical trials have clearly noted a 
deleterious effect, in particular fluid retention, of blocking endothelin receptors. For example, 
phase III clinical trials of 9 for diabetic nephropathy or 5 in the context of oncology of ETA-
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selective compounds led to early study termination due to water retention or increased 
mortality. However, it has been observed in most studies, that the side effects are dose-related 
and that for most trials the dosage applied were likely too high. In cancer, the situation is 
more complex. ETA is important in tumor cell migration, metastasis and proliferation, while 
ETB is critical to angiogenesis and inhibition of anti-tumor immune cell recruitment However, 
the type and grade of cancer, its tissue origin, its stage of progression, the exact cells involved 
and the level of heterogeneity of the tumor must be considered. In human cancer, but possibly 
not in experimental animal tumors, long-term cancer progression required, also impacted on 
the expression of the endothelin axis in cancer stroma, and blocking both receptors may be 
more appropriate for cancer indications. 
A second conclusion reached by clinical trials, and it is not surprising in human therapy, 
was that to achieve optimal therapeutic efficacy drug combination must be considered, adding 
endothelin-receptor antagonists as an adjuvant to other regimens, either concurrent or 
sequential double or even triple therapy. It remains to be demonstrated however, which 
receptor is the better target and which combined-schedule therapy should be proposed to 
patients according to their level of risk. In unpublished experiments using human GBM cells 
in culture and drug combination of the dual ETA/ETB antagonist 2 and alkylating agents 
(carmustine, temozolomide or alkeran), we have shown that cell growth (defined as inhibition 
of DNA synthesis) was additively, rather than synergistically, decreased by combination of 2 
with either carmustine or alkeran.  
In summary, several excellent, orally available, ETA-selective or dual ETA/ETB endothelin-
receptor antagonists, as well as agonists and inhibitors, with acceptable side effects186 have 
been designed, developed and evaluated in preclinical and human clinical settings, showing 
beneficial therapeutic effects in several life-threatening diseases, By themselves, they are not 
curative for these diseases, but they are beneficial in several ways; however, improvement is 
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still needed, in particular, to develop a means to control the side effects associated with 
endothelin-receptor antagonism and achieve more tissue-selective delivery of the therapeutics. 
Strategies to consider may include the design of cell-, tissue- or organ-specific targeting 
therapies, the development of drugs with disease-specific markers, or the use of 
functionalized targeted nanoparticles. 
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